⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MSLE News
Satellos Bioscience Inc. Common Stock
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
globenewswire.com
MSLE
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
globenewswire.com
MSLE
Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
globenewswire.com
MSLE
Satellos to Present Clinical Program Updates at ICNMD 2026
globenewswire.com
MSLE
Satellos Bioscience Announces Results of Annual Meeting of Shareholders
globenewswire.com
MSLE
Satellos to Participate in Upcoming Investor Conferences
globenewswire.com
MSLE
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
globenewswire.com
MSLE
Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference
globenewswire.com
MSLE
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
globenewswire.com
MSLE
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference
globenewswire.com
MSLE